BiotechTV - News

BiotechTV
  • 0.0 (0)
  • 生命科學

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

  1. Physican and Biotech Investor Adam May reacts to this morning's 52 week Rezpeg data in alopecia from Nektar

    58分前

    Physican and Biotech Investor Adam May reacts to this morning's 52 week Rezpeg data in alopecia from Nektar

    He shares his thoughts on the data, the competitive profile of this IL-2 Treg therapy vs JAK inhibitors, and how the overall platform looks for other I&I conditions.

    14 分鐘
  2. 10x Genomics today is announcing Atera, its new in situ spatial transcriptomics platform

    1日前

    10x Genomics today is announcing Atera, its new in situ spatial transcriptomics platform

    Co-Founder and CEO Serge Saxonov walks us through the platform, which can process up to 800 whole-transcriptome samples per year (1 cm² each) on a single instrument, scaling to thousands of samples per year for targeted assays, and has single-cell level sensitivity.

    14 分鐘
  3. Is this analyst the world's biggest bear on the weight loss space? After downgrading Lilly to a sell rating, HSBC's Rajesh Kumar discusses why he thinks pricing factors are being under-appreciated

    3日前

    Is this analyst the world's biggest bear on the weight loss space? After downgrading Lilly to a sell rating, HSBC's Rajesh Kumar discusses why he thinks pricing factors are being under-appreciated

    Plus, discussions on key trial readouts outside of obesity: eplontersen, Lp(a), oral IL-23, and milvexian.

    26 分鐘
  4. Raymond James Biotech Innovation Symposium: Biotech analyst Tiago Fauth shares his read on the mood of investors and discusses companies he covers

    5日前

    Raymond James Biotech Innovation Symposium: Biotech analyst Tiago Fauth shares his read on the mood of investors and discusses companies he covers

    He discusses Praxis, Insmed, Ionis, PTC Therapeutics, Rapport, and United Therapeutics.

    9 分鐘
  5. Raymond James Biotech Innovation Symposium: Korro Bio CEO Ram Aiyer discussed how the company has chosen new RNA editing programs to move forward with this year

    5日前

    Raymond James Biotech Innovation Symposium: Korro Bio CEO Ram Aiyer discussed how the company has chosen new RNA editing programs to move forward with this year

    After experiencing a setback last year with Korro's LNP delivered alpha-1 antitrypsin deficiency program, he describes learnings from that experience and how Korro has new momentum with a galNAc delivered approach targeting urea cycle disorders, hepatic encephalophy, and new alpha-1 program. The company recently closed a $85 private placement.

    12 分鐘
  6. Raymond James Biotech Innovation Symposium: Dyne's CEO John Cox shares an overview of the company's recent landmark DMD data

    5日前

    Raymond James Biotech Innovation Symposium: Dyne's CEO John Cox shares an overview of the company's recent landmark DMD data

    He describes both the biomarker and functional benefits seen in the December data for the company's next-generation exon 51 skipping therapy.

    13 分鐘
  7. Raymond James Biotech Innovation Summit: Checking in with Vera's Founder & CEO Marshall Fordyce ahead of the July 7 FDA decision date for the APRIL & BAFF targeting IgAN treatment Atacicept

    5日前

    Raymond James Biotech Innovation Summit: Checking in with Vera's Founder & CEO Marshall Fordyce ahead of the July 7 FDA decision date for the APRIL & BAFF targeting IgAN treatment Atacicept

    He reminds us of the unmet need for this type of therapy and discusses the planning that Vera has been doing ahead of the decision date.

    8 分鐘
  8. Raymond James Biotech Innovation Symposium: Akebia's CEO John Butler shares an update on the launch of Vafseo and discusses two of the company's pipeline programs

    5日前

    Raymond James Biotech Innovation Symposium: Akebia's CEO John Butler shares an update on the launch of Vafseo and discusses two of the company's pipeline programs

    He describes physician, patient, and payor feedback from this closely watched launch. Plus, praliciguat, and why Akebia bought a targeted complement inhibitor from Q32 Bio.

    8 分鐘
查看全部 (422)

關於

This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.

資料

  • 頻道
    BiotechTV
  • 創作者
    BiotechTV
  • 活躍年份
    2025年 - 2026年
  • 單集
    422
  • 分級
    兒童適宜
  • 版權
    © BiotechTV
  • 節目網站
    BiotechTV - News

BiotechTV的更多作品

你可能也會喜歡